(Q37827872)

23 August 2017

1 reference

title

Strategies to manage antifungal drug resistance (English)

1 reference

23 August 2017

2

John R Perfect

1 reference

23 August 2017

Hsiang-Kuang Tseng

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

12

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

241-256

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

23 August 2017

1 reference

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Management of Candida species infections in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Caspofungin: the first in a new class of antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Micafungin: a new echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Anidulafungin: a new echinocandin with a novel profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

When primary antifungal therapy fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Treatment of pan-drug resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Clostridium difficile: from obscurity to superbug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Resistance mechanisms in clinical isolates of Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Resistance to echinocandin-class antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Novel FKS mutations associated with echinocandin resistance in Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Breakthrough invasive candidiasis in patients on micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Increasing incidence of Candida parapsilosis candidemia with caspofungin usage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Changes in causes of death over time after treatment for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Trends in antifungal susceptibility testing using CLSI reference and commercial methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Has antifungal susceptibility testing come of age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Antifungal chemical compounds identified using a C. elegans pathogenicity assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

A small protein that fights fungi: AFP as a new promising antifungal agent of biotechnological value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

The use of chitosan to damage Cryptococcus neoformans biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Antifungal activity of 25-azalanosterol against Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Antifungal activity of the essential oil of Thymus x viciosoi against Candida, Cryptococcus, Aspergillus and dermatophyte species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Non-culture-based diagnostics for opportunistic fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Development of novel real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Should the consensus guidelines' specific criteria for the diagnosis of invasive fungal infection be changed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Aerosolized antifungal prophylaxis: the winds of change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Immunotherapy for fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Granulocyte colony-stimulating factor and other cytokines in antifungal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Randomized phase III study of granulocyte transfusions in neutropenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Interferon- gamma as an antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Human dectin-1 deficiency and mucocutaneous fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

A novel glyco-conjugate vaccine against fungal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Immunomodulators as an antimicrobial tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Immune restoration disease after antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Pharmacokinetics and pharmacodynamics of antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Invasive Candida species infection: the importance of adequate empirical antifungal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Clinically relevant drug interactions of current antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Reduction of Invasive Aspergillosis Incidence among Immunocompromised Patients after Control of Environmental Exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.517195

10.1517/14656566.2010.517195

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference